MA45539A - Dihydropyranopyrimidines pour le traitement d'infections virales - Google Patents

Dihydropyranopyrimidines pour le traitement d'infections virales

Info

Publication number
MA45539A
MA45539A MA045539A MA45539A MA45539A MA 45539 A MA45539 A MA 45539A MA 045539 A MA045539 A MA 045539A MA 45539 A MA45539 A MA 45539A MA 45539 A MA45539 A MA 45539A
Authority
MA
Morocco
Prior art keywords
dihydropyranopyrimidines
treatment
viral infections
infections
viral
Prior art date
Application number
MA045539A
Other languages
English (en)
Inventor
Laurent Calmus
Ludwig Paul Cooymans
Werner Constant Johan Embrechts
Jérôme Émile Georges Guillemont
Tim Hugo Maria Jonckers
Gowan David Craig Mc
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA45539A publication Critical patent/MA45539A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA045539A 2016-07-01 2017-06-30 Dihydropyranopyrimidines pour le traitement d'infections virales MA45539A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16177401 2016-07-01

Publications (1)

Publication Number Publication Date
MA45539A true MA45539A (fr) 2019-05-08

Family

ID=56292567

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045539A MA45539A (fr) 2016-07-01 2017-06-30 Dihydropyranopyrimidines pour le traitement d'infections virales

Country Status (10)

Country Link
US (2) US11053256B2 (fr)
EP (1) EP3478688A1 (fr)
JP (1) JP7171444B2 (fr)
CN (1) CN109476675B (fr)
AU (1) AU2017289418B2 (fr)
CA (1) CA3027471A1 (fr)
IL (1) IL263972A (fr)
MA (1) MA45539A (fr)
SG (1) SG11201811448RA (fr)
WO (1) WO2018002319A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03782B (fr) 2011-04-08 2021-04-20 Janssen Sciences Ireland Unlimited Co Dérivés de la pyrimidine pour le traitement des infections virales
MD20170081A2 (ro) 2015-03-04 2018-03-31 Gilead Sciences, Inc. Compuşi 4,6-diamino-pirido[3,2-D]pirimidină modulatori ai receptorilor de tip Toll
WO2018002319A1 (fr) * 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines pour le traitement d'infections virales
CA3035346A1 (fr) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Composes modulateurs du recepteur de type toll
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
ES2912945T3 (es) 2016-09-29 2022-05-30 Janssen Sciences Ireland Unlimited Co Profármacos de pirimidina para el tratamiento de infecciones virales y otras enfermedades
IL265921B2 (en) 2016-10-14 2024-05-01 Prec Biosciences Inc Transgenic meganonucleases specific for recognition sequences in the hepatitis B virus genome
EP3728283B1 (fr) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
EP3759109B1 (fr) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Composés de pyrrolizine substitués en tant qu'inhibiteurs de réplication du virus de l'hépatite b
TW201945003A (zh) * 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
EP3774883A1 (fr) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b
KR20200140867A (ko) 2018-04-06 2020-12-16 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’-環二核苷酸
WO2020028097A1 (fr) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
WO2020178770A1 (fr) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. Dinucléotides 3'3'-cycliques et leurs promédicaments
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021067181A1 (fr) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Vaccins contre le virus de l'hépatite b et méthodes de traitement du vhb
CN116057068A (zh) 2019-12-06 2023-05-02 精密生物科学公司 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2022031011A1 (fr) 2020-08-04 2022-02-10 성균관대학교산학협력단 Ensemble adjuvant à action cinétique
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途
EP4194006A1 (fr) 2020-08-04 2023-06-14 Progeneer Inc. Vaccin à arnm comprenant un adjuvant permettant un contrôle cinétique
WO2022241134A1 (fr) 2021-05-13 2022-11-17 Gilead Sciences, Inc. Combinaison d'un composé de modulation de tlr8 et agent thérapeutique anti-arnsi de vhb
WO2022271677A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
CA3222439A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composes modulant les diacylglycerol kinases
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359413A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
WO2024073502A1 (fr) * 2022-09-28 2024-04-04 Accutar Biotechnology Inc. Composés hétérocycliques utilisés en tant qu'inhibiteurs de ligase e3

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2610889B2 (ja) 1987-09-03 1997-05-14 日本臓器製薬株式会社 新規架橋アデニン誘導体
BR9407298A (pt) * 1993-08-19 1996-10-01 Janssen Pharmaceutica Nv Diidropiranopiridinas vasoconstritoras substituidas
TW552261B (en) 1996-07-03 2003-09-11 Japan Energy Corp Novel purine derivative
AU735401B2 (en) 1996-08-28 2001-07-05 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
WO1998014448A1 (fr) 1996-10-04 1998-04-09 Kyorin Pharmaceutical Co., Ltd. Derives de pyrazolopyridylpyridazinone et procede de preparation des ces derniers
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
NZ504800A (en) 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
IL137922A0 (en) 1998-02-17 2001-10-31 Tularik Inc Anti-viral pyrimidine derivatives
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP4342007B2 (ja) 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
JP4315300B2 (ja) 1998-08-10 2009-08-19 大日本住友製薬株式会社 新規なキナゾリン誘導体
JP4497340B2 (ja) 1998-08-27 2010-07-07 大日本住友製薬株式会社 ピリミジン誘導体
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
CA2323008C (fr) 1999-10-11 2005-07-12 Pfizer Inc. Composes pharmaceutiques actifs
WO2002088079A2 (fr) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Inhibiteurs doubles de pde 7 et pde 4
WO2003055890A1 (fr) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Composes derives de thienopyrimidine utilises comme inhibiteurs de la prolylpeptidase, inducteurs d'apoptose et agents de traitement anticancereux
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
EP1552842A1 (fr) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Derives bicycliques de pyrimidine
CA2497765A1 (fr) 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Co., Ltd. Nouveau compose d'adenine et son application
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
WO2005007672A2 (fr) 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Antagonistes des recepteurs toll (tlr) pour petites molecules
AP2006003542A0 (en) 2003-09-05 2006-04-30 Anadys Pharmaceuticals Inc Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus.
TWI392678B (zh) 2004-03-26 2013-04-11 Dainippon Sumitomo Pharma Co 9-取代-8-氧基腺嘌呤化合物
JPWO2005092892A1 (ja) 2004-03-26 2008-02-14 大日本住友製薬株式会社 8−オキソアデニン化合物
WO2007084413A2 (fr) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Procedes de traitement de l’hepatite c
US7923554B2 (en) 2004-08-10 2011-04-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
WO2006050843A1 (fr) 2004-11-09 2006-05-18 F. Hoffmann-La Roche Ag Composes aminoquinazolines
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
BRPI0611435A2 (pt) 2005-05-04 2010-09-08 Pfizer Ltd derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
TW200716631A (en) 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
US7994360B2 (en) 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
CN101296907B (zh) 2005-09-01 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
WO2007056208A2 (fr) 2005-11-02 2007-05-18 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose et utilisation de ceux-ci
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
WO2007093901A1 (fr) 2006-02-17 2007-08-23 Pfizer Limited Dérivés de 3-déazapurine en tant que modulateurs de tlr7
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009077A2 (fr) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Dérivés quinazoline 4,6-disubstitués et 2,4,6-trisubstitués et compositions pharmaceutiques utiles pour traiter des infections virales
KR20090077780A (ko) * 2006-09-15 2009-07-15 바스프 에스이 4급화 질소-함유 단량체 기재의 양쪽성 공중합체
TW200829594A (en) 2006-12-07 2008-07-16 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
AU2007335962B2 (en) 2006-12-20 2012-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
PL2510946T3 (pl) 2007-02-07 2015-12-31 Univ California Koniugaty syntetycznych agonistów tlr i ich zastosowania
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ[3,2−d]ピリミジン誘導体及びこれを有効成分とする医薬組成物
US8067413B2 (en) 2007-03-19 2011-11-29 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
WO2008114819A1 (fr) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. Nouveau composé d'adénine
EP2152674B1 (fr) 2007-05-22 2011-08-03 Boehringer Ingelheim International GmbH Inhibiteurs de benzimidazolone chymase
EP2170888B1 (fr) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Dérivés de purine et leur utilisation comme modulateurs du récepteur de type toll-7
EP2187883A2 (fr) 2007-08-10 2010-05-26 Genelabs Technologies, Inc. Entités chimiques bicycliques azotées pour traiter les infections virales
BRPI0815979A2 (pt) 2007-08-28 2017-06-13 Irm Llc compostos e composições com inibidores de quinase, bem como uso dos mesmos
WO2009030998A1 (fr) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Composés pyrimidine utilisés comme agonistes du récepteur de type toll (tlr)
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
DK2238142T3 (da) 2007-12-24 2012-10-08 Janssen R & D Ireland Makrocykliske indoler som hepatitis C-virusinhibitorer
EP2259788A4 (fr) 2008-02-07 2011-03-16 Univ California Traitement des maladies de la vessie avec un activateur de tlr7
EP2271345B1 (fr) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Inhibiteurs de la protéase hcv ns3
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
SG175796A1 (en) 2009-05-21 2011-12-29 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β-類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
EP2491033A4 (fr) 2009-10-20 2013-03-13 Eiger Biopharmaceuticals Inc Azaindazoles pour traiter une infection par le virus flaviviridae
KR101793300B1 (ko) 2009-10-22 2017-11-02 길리애드 사이언시즈, 인코포레이티드 특히 바이러스성 감염의 치료에 유용한 퓨린 또는 데아자퓨린의 유도체
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노[3,2-d]피리미딘 화합물
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012066335A1 (fr) 2010-11-19 2012-05-24 Astrazeneca Ab Composés phénol en tant qu'agonistes du récepteur 7 de type toll
WO2012067269A1 (fr) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Composés aminoalcoxyphényle et leur utilisation dans le traitement de maladies
ME03782B (fr) 2011-04-08 2021-04-20 Janssen Sciences Ireland Unlimited Co Dérivés de la pyrimidine pour le traitement des infections virales
EA028254B1 (ru) 2011-05-18 2017-10-31 Янссен Сайенсиз Айрлэнд Юси Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CN107011346B (zh) 2011-11-09 2020-06-16 爱尔兰詹森科学公司 用于治疗病毒感染的嘌呤衍生物
IN2014MN01736A (fr) * 2012-02-08 2015-07-10 Janssen R & D Ireland
NZ700928A (en) 2012-04-24 2017-06-30 Vertex Pharma Dna-pk inhibitors
BR112015000615B1 (pt) 2012-07-13 2022-05-31 Janssen Sciences Ireland Uc Purinas macrocíclicas para o tratamento de infecções virais e composição farmacêutica que as compreende
IN2015MN00478A (fr) 2012-08-10 2015-09-04 Janssen Sciences Ireland Uc
EP2712866A1 (fr) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) Dérivés de 1,2,4-triazine pour le traitement d'infections virales
WO2014053595A1 (fr) 2012-10-05 2014-04-10 Janssen R&D Ireland Dérivés d'acylaminopyrimidine pour le traitement d'infections virales et d'autres maladies
CN104837840B (zh) 2012-10-10 2017-08-08 爱尔兰詹森科学公司 用于治疗病毒感染及其他疾病的吡咯并[3,2‑d]嘧啶衍生物
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
JP6336036B2 (ja) 2013-03-29 2018-06-06 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療のための大環状デアザプリノン
MX368625B (es) 2013-07-30 2019-10-08 Janssen Sciences Ireland Uc Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales.
EP3166938A4 (fr) 2014-07-11 2018-01-17 Northwestern University Échafaudages 2-imidazolyl-pyrimidine en tant qu'inhibiteurs puissants et sélectifs de l'oxyde nitrique synthase neuronale
WO2018002319A1 (fr) * 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines pour le traitement d'infections virales

Also Published As

Publication number Publication date
CA3027471A1 (fr) 2018-01-04
IL263972A (en) 2019-01-31
CN109476675B (zh) 2022-12-09
WO2018002319A1 (fr) 2018-01-04
US11053256B2 (en) 2021-07-06
US20190322678A1 (en) 2019-10-24
AU2017289418B2 (en) 2021-06-03
CN109476675A (zh) 2019-03-15
SG11201811448RA (en) 2019-01-30
JP2019524662A (ja) 2019-09-05
AU2017289418A1 (en) 2019-01-03
US20210387997A1 (en) 2021-12-16
EP3478688A1 (fr) 2019-05-08
JP7171444B2 (ja) 2022-11-15

Similar Documents

Publication Publication Date Title
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA45192A (fr) Traitement d'association
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA49144A (fr) Polythérapies pour le traitement du cancer
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA41449A (fr) Polythérapies pour le traitement de cancers
MA48637A (fr) Polythérapies pour le traitement du cancer
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA43811A (fr) Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
MA50409A (fr) Polythérapies pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA43230A (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
RS64869B1 (sr) Emulzije za lečenje vaginalnih infekcija